New drug combo is shown to shrink ovarian cancer tumours

There is hope for women with a rare type of ovarian after a clinical trial showed that a new combination of drugs can reduce the size of tumours.

Almost a third (31%) of women with low-grade serous ovarian cancer, which does not respond well to chemotherapy, saw their tumours shrink or stop growing when taking a combination of avutometinib and defactinib.

The results in patients who had a mutation in a gene called KRAS were even more promising, with 44% of patients seeing their tumour shrink.

Load More